Mutations in TP53 are reported to drive the development and sustained expansion of tumours through three different, albeit not mutually exclusive properties: loss of wild-type (wt) TP53 function (LOF), dominant-negative effects (DNE) on wt TP53 (which are seen during the early stages of neoplastic transformation when cells express both mutant TP53/TRP53 and wt TP53/TRP53) and neomorphic gain-of-function (GOF) effects. This evidence concerns the gene TP53 and neoplasm.